Knight Therapeutics Inc. Celebrates its First Decade of Success
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.
- MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.
- Knight has invested over $925 million to build its unique pan-American (ex US) platform of innovative and branded generic pharmaceuticals.
- Today, Knight has over 700 talented employees operating in Canada and 10 Latin American markets.
- Since the completion of the acquisition of Biotoscana, Knight has entered into 11 new partnerships for 13 innovative and branded generic products.